Alkahest achieves positive results in clinical trials of the treatment of Alzheimer's disease in Phase 2 of the research therapy GRF6019
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Alkahest(http://announced positive results in its treatment of GRF6019, a phase 2 clinicaltrial(http://in patients with mild to moderate Alzheimer's disease (AD)GRF6019 consists of specific protein components extracted from young people's plasma, and in this clinical trial it prevents cognitive decline in patients during trialsGRF6019, a research-based treatment for Alzheimer's disease developed by the company, is a plasma component with apatented(http://, containing a variety of proteins developed and supplied by partner Grifols, which stimulates the production of nerve cells and improves cognitive ability in animal models, and relieves nerve inflammationThe subjects were administered in 100 mL or 250 mL of GRF6019 intravenously for 5 consecutive days in week 1 and administered the drug for 5 consecutive days in week 13 without treatment at a 12-week intervalGRF6019 was safe and well tolerated, and cognitive ability tests showed that subjects did not experience cognitive decline during the six-month trial
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
